JP2022520138A5 - - Google Patents

Info

Publication number
JP2022520138A5
JP2022520138A5 JP2021511635A JP2021511635A JP2022520138A5 JP 2022520138 A5 JP2022520138 A5 JP 2022520138A5 JP 2021511635 A JP2021511635 A JP 2021511635A JP 2021511635 A JP2021511635 A JP 2021511635A JP 2022520138 A5 JP2022520138 A5 JP 2022520138A5
Authority
JP
Japan
Prior art keywords
cell surface
specific cell
lineage
surface antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048662 external-priority patent/WO2020047164A1/en
Publication of JP2022520138A publication Critical patent/JP2022520138A/ja
Publication of JP2022520138A5 publication Critical patent/JP2022520138A5/ja
Priority to JP2024122163A priority Critical patent/JP2024164023A/ja
Priority to JP2024193499A priority patent/JP2025032083A/ja
Pending legal-status Critical Current

Links

JP2021511635A 2018-08-28 2019-08-28 遺伝子操作された造血幹細胞およびそれらの使用 Pending JP2022520138A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024122163A JP2024164023A (ja) 2018-08-28 2024-07-29 遺伝子操作された造血幹細胞およびそれらの使用
JP2024193499A JP2025032083A (ja) 2018-08-28 2024-11-05 遺伝子操作された造血幹細胞およびそれらの使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862723993P 2018-08-28 2018-08-28
US62/723,993 2018-08-28
US201862728061P 2018-09-06 2018-09-06
US62/728,061 2018-09-06
US201962789440P 2019-01-07 2019-01-07
US62/789,440 2019-01-07
US201962809202P 2019-02-22 2019-02-22
US62/809,202 2019-02-22
PCT/US2019/048662 WO2020047164A1 (en) 2018-08-28 2019-08-28 Genetically engineered hematopoietic stem cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024122163A Division JP2024164023A (ja) 2018-08-28 2024-07-29 遺伝子操作された造血幹細胞およびそれらの使用

Publications (2)

Publication Number Publication Date
JP2022520138A JP2022520138A (ja) 2022-03-29
JP2022520138A5 true JP2022520138A5 (cg-RX-API-DMAC7.html) 2022-09-06

Family

ID=67928915

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021511635A Pending JP2022520138A (ja) 2018-08-28 2019-08-28 遺伝子操作された造血幹細胞およびそれらの使用
JP2024122163A Pending JP2024164023A (ja) 2018-08-28 2024-07-29 遺伝子操作された造血幹細胞およびそれらの使用
JP2024193499A Pending JP2025032083A (ja) 2018-08-28 2024-11-05 遺伝子操作された造血幹細胞およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024122163A Pending JP2024164023A (ja) 2018-08-28 2024-07-29 遺伝子操作された造血幹細胞およびそれらの使用
JP2024193499A Pending JP2025032083A (ja) 2018-08-28 2024-11-05 遺伝子操作された造血幹細胞およびそれらの使用

Country Status (12)

Country Link
US (9) US11389485B2 (cg-RX-API-DMAC7.html)
EP (2) EP3844187A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022520138A (cg-RX-API-DMAC7.html)
KR (1) KR20220036908A (cg-RX-API-DMAC7.html)
CN (1) CN113423725A (cg-RX-API-DMAC7.html)
AU (1) AU2019333104C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003670A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110837A1 (cg-RX-API-DMAC7.html)
IL (1) IL281113B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002415A (cg-RX-API-DMAC7.html)
SG (1) SG11202101994XA (cg-RX-API-DMAC7.html)
WO (1) WO2020047164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
AU2020280103A1 (en) * 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
WO2021041977A1 (en) * 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
AU2020338011A1 (en) * 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
EP4048790A4 (en) * 2019-10-22 2024-03-27 Fred Hutchinson Cancer Center BASE EDITOR-MEDIATED CD33 REDUCTION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
CN116157135A (zh) * 2020-06-03 2023-05-23 纽约市哥伦比亚大学理事会 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法
EP4204564A1 (en) * 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cd123 modification
EP4204565A1 (en) * 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
WO2022056489A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
WO2022067240A1 (en) * 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) * 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
WO2022081828A1 (en) * 2020-10-16 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment with a combination of agents
WO2022104090A1 (en) 2020-11-13 2022-05-19 Vor Biopharma Inc. Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
CN116744963A (zh) * 2020-11-13 2023-09-12 Vor生物制药股份有限公司 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物
AU2022216614B2 (en) * 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
EP4381062A1 (en) * 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
US20240408234A1 (en) * 2021-09-14 2024-12-12 Vor Biopharma Inc. Compositions and methods for multiplex base editing in hematopoietic cells
EP4430186A1 (en) * 2021-11-09 2024-09-18 Vor Biopharma Inc. Compositions and methods for erm2 modification
AU2022426854A1 (en) * 2021-12-31 2024-06-13 The Trustees Of Columbia University In The City Of New York Bispecific molecules to target the first cell
US20250179531A1 (en) * 2022-02-25 2025-06-05 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
CN118843688A (zh) * 2022-03-04 2024-10-25 株式会社图尔金 低免疫原性干细胞、由干细胞分化或衍生的低免疫原性细胞及其制备方法
US20250295695A1 (en) * 2022-04-04 2025-09-25 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
JP2025513855A (ja) 2022-04-11 2025-04-30 ブイオーアール バイオファーマ インコーポレーテッド 結合剤及びその使用方法
CN114743598B (zh) * 2022-06-14 2022-09-02 湖南大学 一种基于信息论检测新冠病毒谱系间重组的方法
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
IL320069A (en) * 2022-10-05 2025-06-01 Garuda Therapeutics Inc Aged hematopoietic stem cells and their descendants
CN118684759A (zh) * 2023-01-17 2024-09-24 武汉大学 用于治疗急性髓系白血病的成分和方法
WO2024168312A1 (en) * 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
JP2026516593A (ja) * 2023-04-03 2026-05-26 ウニバズィテート バーゼル 細胞治療に使用するためのcd33の識別可能な表面タンパク質変異体
EP4713363A1 (en) 2023-05-15 2026-03-25 Syzygymed Inc Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2026019837A1 (en) * 2024-07-17 2026-01-22 Board Of Regents, The University Of Texas System Compositions and methods for overcoming t-cell exhaustion

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
EP0648835A1 (en) 1993-10-14 1995-04-19 The Procter & Gamble Company Use of alkaline polyammonium salts to increase cationic density in fabric softeners
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5756910A (en) 1996-08-28 1998-05-26 Burgett, Inc. Method and apparatus for actuating solenoids in a player piano
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
JPWO2010110346A1 (ja) 2009-03-24 2012-10-04 独立行政法人理化学研究所 白血病幹細胞マーカー
JP6073135B2 (ja) 2009-10-19 2017-02-01 トライステム・トレイディング・(キプロス)・リミテッドTriStem Trading (Cyprus) Limited 再プログラム化成熟成体細胞を用いる治療
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
EP2833591A1 (en) 2013-07-31 2015-02-04 Siemens Aktiengesellschaft Subsea data communication interface unit
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
ES2765710T3 (es) 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
EP3129485B2 (en) 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
WO2015195547A1 (en) 2014-06-16 2015-12-23 University Of Washington Methods for controlling stem cell potential and for gene editing in stem cells
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
CN113699113A (zh) 2014-09-16 2021-11-26 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
KR101799975B1 (ko) 2014-10-31 2017-11-21 에스케이씨하이테크앤마케팅(유) 액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CN107787367B (zh) * 2015-04-06 2021-10-26 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
CA2994746A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
IL258491B2 (en) 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3370741B1 (en) 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
WO2017091615A1 (en) 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies
CA3009308A1 (en) 2015-12-23 2017-06-29 Chad Albert COWAN Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
EP3439700A4 (en) 2016-04-06 2020-01-01 University of Florida Research Foundation, Inc. BIOMARKER FOR ANTILEUCEMIC THERAPY
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US11466291B2 (en) 2016-07-06 2022-10-11 Cellectis Sequential gene editing in primary immune cells
SMT202100555T1 (it) 2016-10-21 2021-11-12 Inst Nat Sante Rech Med Metodi per promuovere la risposta di cellule t
US20190365806A1 (en) 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
CN110249052B (zh) 2016-12-30 2024-04-12 爱迪塔斯医药公司 合成的指导分子、组合物和与其相关的方法
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
KR20190140943A (ko) 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3676372A4 (en) 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33
US12359223B2 (en) 2018-01-30 2025-07-15 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
CN111699254A (zh) 2018-02-08 2020-09-22 齐默尔根公司 使用crispr在棒状杆菌属中进行基因组编辑
TWI669677B (zh) 2018-03-07 2019-08-21 光陽工業股份有限公司 充電座管理方法、用於充電座管理方法的伺服器及充電座
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
WO2020028533A1 (en) 2018-08-01 2020-02-06 Yale University Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
SG11202103832SA (en) 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
KR20210116526A (ko) 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
JP7784707B2 (ja) 2019-01-16 2025-12-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 系統特異的抗原の阻害のための組成物および方法
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
AU2020280103A1 (en) * 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
EA202191979A1 (ru) 2019-05-24 2021-11-01 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Композиции и способы ингибирования линиеспецифических антигенов
CA3144356A1 (en) 2019-06-21 2020-12-24 Function Oncology, Inc. A genetic pharmacopeia for comprehensive functional profiling of human cancers
AU2020338011A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
WO2021041977A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
EP4204564A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cd123 modification
EP4204565A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
AU2021413252A1 (en) * 2020-12-31 2023-06-08 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
EP4381062A1 (en) 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
US20240408234A1 (en) * 2021-09-14 2024-12-12 Vor Biopharma Inc. Compositions and methods for multiplex base editing in hematopoietic cells
EP4433512A4 (en) 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
JP2025508721A (ja) 2022-02-18 2025-04-10 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド 細胞表面受容体のエピトープ操作

Similar Documents

Publication Publication Date Title
Volovat et al. Oncolytic virotherapy: a new paradigm in cancer immunotherapy
Davola et al. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Sepich-Poore et al. The microbiome and human cancer
Muthukutty et al. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective
Antsiferova et al. Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice
Kallert et al. Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy
Williams et al. Preclinical models of HPV+ and HPV− HNSCC in mice: an immune clearance of HPV+ HNSCC
Hamada et al. Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer
US11617765B2 (en) Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cells
Chulpanova et al. Recombinant viruses for cancer therapy
Li et al. Plasmablastic lymphoma: current knowledge and future directions
CN105307671A (zh) 增强过继细胞疗法
Bascuas et al. Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice
JP2022534813A5 (cg-RX-API-DMAC7.html)
Jazowiecka-Rakus et al. Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma
Feng et al. Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer
JP2016513115A5 (cg-RX-API-DMAC7.html)
Deng et al. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy
Lapp et al. Viral oncolysis—can insights from measles be transferred to canine distemper virus?
EP3436065B1 (en) Anti-cancer oncolytic virus combination therapies and elite responder selection platforms
Lam et al. The innovative evolution of cancer gene and cellular therapies
Takahashi et al. Indolent T-cell lymphoproliferative disorder of the stomach successfully treated by radiotherapy
Hasanzadeh et al. Applications of innovation technologies for personalized cancer medicine: stem cells and gene-editing tools
Bhadra et al. Absence of both IL-7 and IL-15 severely impairs the development of CD8+ T cell response against Toxoplasma gondii
Hawkins et al. Lethal giant larvae 1 tumour suppressor activity is not conserved in models of mammalian T and B cell leukaemia